- Home
- LIDR vs SABS Comparison
LIDR vs SABS Comparison
Compare LIDR & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- SABS
- Stock Information
- Founded
- LIDR 2013
- SABS 2014
- Country
- LIDR United States
- SABS United States
- Employees
- LIDR N/A
- SABS N/A
- Industry
- LIDR Auto Parts:O.E.M.
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- LIDR Consumer Discretionary
- SABS Health Care
- Exchange
- LIDR Nasdaq
- SABS Nasdaq
- Market Cap
- LIDR 14.8M
- SABS 15.8M
- IPO Year
- LIDR N/A
- SABS N/A
- Fundamental
- Price
- LIDR $0.92
- SABS $1.78
- Analyst Decision
- LIDR Hold
- SABS Strong Buy
- Analyst Count
- LIDR 1
- SABS 5
- Target Price
- LIDR N/A
- SABS $11.80
- AVG Volume (30 Days)
- LIDR 577.6K
- SABS 17.6K
- Earning Date
- LIDR 08-04-2025
- SABS 08-07-2025
- Dividend Yield
- LIDR N/A
- SABS N/A
- EPS Growth
- LIDR N/A
- SABS N/A
- EPS
- LIDR N/A
- SABS N/A
- Revenue
- LIDR $246,000.00
- SABS $377,835.00
- Revenue This Year
- LIDR $2,677.23
- SABS N/A
- Revenue Next Year
- LIDR $409.09
- SABS N/A
- P/E Ratio
- LIDR N/A
- SABS N/A
- Revenue Growth
- LIDR N/A
- SABS N/A
- 52 Week Low
- LIDR $0.49
- SABS $1.00
- 52 Week High
- LIDR $4.30
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- LIDR 65.47
- SABS 49.33
- Support Level
- LIDR $0.71
- SABS $1.60
- Resistance Level
- LIDR $0.88
- SABS $1.87
- Average True Range (ATR)
- LIDR 0.09
- SABS 0.11
- MACD
- LIDR 0.00
- SABS -0.01
- Stochastic Oscillator
- LIDR 89.21
- SABS 62.07
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.